RxDoctor Payments Data

Jessica Brown, MD

Cardiovascular Disease · The Woodlands, TXNPI 1326391293

Payments from drug & device makers

$2,749in general payments, 2019–2025

Across 48 payments — averaging $57.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$314
  • Impulse Dynamics (USA) Inc.$274
  • Cvrx, Inc.$266
  • Edwards Lifesciences$208
  • Amgen$158
  • plus $473 from 8 others

What the payments were for

  • Travel & lodging$40015%
  • Food & beverage$2,23481%
  • Education$1154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,749 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$299,250
Medicare patients
863
Services billed
2,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban434$429,743
AdempasRiociguat27$382,374
OpsumitMacitentan25$309,581
EntrestoSacubitril/Valsartan252$275,314
JardianceEmpagliflozin155$135,190
Repatha SureclickEvolocumab72$70,529
XareltoRivaroxaban45$57,665
FarxigaDapagliflozin Propanediol39$36,787
Repatha SyringeEvolocumab25$27,453
Praluent PenAlirocumab16$17,836
BrilintaTicagrelor25$17,390
OzempicSemaglutide11$10,029
Metoprolol Succinate436$7,193
Dofetilide36$6,500
Ranolazine ErRanolazine37$6,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$141$309,58125 claims
NovartisEntresto$31$275,314252 claims
Johnson & JohnsonXarelto$34$57,66545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →